	5 <sup>th</sup> Hepatitis C Technical Advisory Group (TAG) Meeting: Science Symposium	
TIME	PRESENTATIONS November 18, 2019	SPEAKERS
9:00-9:30	Welcome and Opening Remarks	Dr. Amiran Gamkrelidze, NCDC
9.00-9.30	Welcome and Opening Kemarks	Dr. Francisco Averhoff, US CDC
	Activities of the Scientific Committee of the National Hepatitis C Elimination	Dr. Tinatin Kuchuloria, TEPHINET
	Program, 2016-2019	DI. IIIIatiii Kuchulona, Terriiiver
9:30-10:15	Immediate and Long-term Clinical Outcomes of DAA Treatment	
	<ul> <li>Assessment of the national hepatitis C elimination program: treatment</li> </ul>	Dr. Lali Sharvadze, IDACIRC
	outcomes and associated factors, 2015-2019	
	<ul> <li>Challenges to HCV micro-elimination in HIV/HCV co-infection in Georgia</li> </ul>	Dr. Nikoloz Chkhartishvili, IDACIRC
	<ul> <li>Long-term health outcome among HCV patients with advanced liver fibrosis</li> </ul>	<b>Dr. Maia Kajaia</b> , Health Research Union (HRU)
	treated through the HCV elimination program	
10:15-11:15	Evaluation of Diagnostics and Treatment Delivery Models Both at Specialized and	
	Non-specialized HCV Care Settings	
	<ul> <li>Integrating HCV screening and simplified treatment services in primary</li> </ul>	<b>Dr. Akaki Abutidze,</b> IDACIRC
	healthcare	
	<ul> <li>Effectiveness of three models of HCV diagnostics in harm reduction: Impact</li> </ul>	<b>Dr. Sonjelle Shilton,</b> FIND
	on linkage to care—A pilot project in Georgia	
	<ul> <li>Integration of HCV RNA testing on existing GeneXperts in Georgia to assist</li> </ul>	<b>Dr. Maia Japaridze,</b> FIND
	in current HCV care decentralization efforts	
11:15-11:45	BREAK	
11:45-12:30	Novel Approaches to Laboratory Diagnostics	
	<ul> <li>Evaluation study of HCV Rapid Diagnostic Tests (RDTs), dry blood spots</li> </ul>	<b>Dr. Maia Alkhazashvili,</b> NCDC
	for HCV RNA testing, and the Genedrive® HCV ID Kit in Georgia	
	<ul> <li>Evaluation of the diagnostic performance of HCVcAg as test of cure in for</li> </ul>	<b>Dr. Nazibrola Chitadze,</b> NCDC
	hepatitis C among PWID in Georgia	
	<ul> <li>Using next generation sequencing (NGS) capacity for hepatitis C</li> </ul>	Dr. Adam Kotorashvili, NCDC
	surveillance in Georgia	
12:30-1:00	Surveillance	
	<ul> <li>Establishing a Georgian PWID cohort study to estimate incidence of HCV</li> </ul>	Dr. Ketevan Shermadini, IDACIRC
	infection	
	HCV reinfection in people living with HIV in Georgia	<b>Dr. Pati Gabunia,</b> IDACIRC
1:00-2:00	LUNCH	

2:00-2:30	Surveillance	
	HCV-attributable hepatocellular carcinoma among persons with	<b>Dr. Ana Aslanikashvili</b> , NCDC
	hepatobiliary cancer diagnoses in Georgia: 2015-2016	
	<ul> <li>Impact on mortality of HCV treatment with direct acting anti-viral</li> </ul>	Dr. Lia Gvinjilia, TEPHINET
	medications, Georgia, 2015-2018	
2:30-2:45	Economic Evaluation	
	Estimation of the cost effectiveness of the HCV treatment program in	<b>Dr. Josephine Walker,</b> University of Bristol
	Georgia	
2:45-3:15	BREAK	
3:15-4:00	Hepatitis B	
	<ul> <li>Prevalence and risk factors for the hepatitis B infection – 2015 serosurvey</li> </ul>	<b>Dr. Ana Kasradze,</b> NCDC
	results	
	Progress and challenges in HBV prevention, care and treatment	Dr. Mamuka Zakalashvili, Clinic Mrcheveli
	Epidemiology and treatment outcomes of HBV infection among HCV	Dr. Maia Butsashvili, Health Research Union
	patients treated with Direct Acting Antivirals (DAAs)	
4:00-4:45	Mother-to -Child Transmission of Viral Hepatitis B and C	
	Overview of the maternal and child state program in Georgia	<b>Dr. Vladimer Getia</b> , NCDC
	HCV Screening and linkage to care in antenatal clinics	Dr. Muazzam Nasrullah, US CDC
	Knowledge and perceived risk of HCV infection among women of	Dr. Tinatin Abzianidze, Health Research Union
	reproductive age in Georgia	
4:45-5:00	Final Remarks	Dr. Amiran Gamkrelidze, NCDC

5 <sup>th</sup> Hepatitis C Technical Advisory Group (TAG) Meeting: Day 1 November 19, 2019		
8:30-9:00	Registration	
9:00-9:30	Welcome and Opening Remarks	Ekaterine Tikaradze, Minister of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia Ms. Elizabeth Rood, Chargé d'Affaires, US Embassy Dr. Carolyn Wester, US CDC Dr. Betty Chiang, Gilead Sciences Dr. Silviu Domente, WHO Georgia Office Head
9:30-10:00	Introduction of TAG Members and Role of the TAG  • Purpose of the meeting and overview of agenda  • Introduction of TAG members  • Review 2018 TAG recommendations	Dr. Carolyn Wester, US CDC (Chair) & Dr. Margaret Hellard, Burnet Institute, Australia (Co-Chair)
10:00-10:30	Progress and Challenges of the HCV Elimination Program in Georgia 2015-2019	<b>Dr. Tamar Gabunia,</b> Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia (MOH)
10:30-11:00	Media Coverage/Break	
11:00-11:15	The interim impact and ongoing treatment requirements for achieving HCV elimination in Georgia	<b>Dr. Peter Vickerman</b> , Bristol University, UK
11:15-11:45	Key issues and challenges for achieving HCV elimination in Georgia	<b>Dr. Francisco Averhoff,</b> US CDC
11:45-1:30	Identify Persons Infected with HCV (and Linked to Care)	TAG moderators: Dr. Carlos Del Rio, Emory University, USA & Dr. Sharon Hutchinson, National Health Service, Scotland, UK Discussants: Irma Khonelidze, NCDC, Alexander Turdziladze, NCDC, Vladimer Getia, NCDC, Muazzam Nasrullah, US CDC
11:45-12:15	TAG 2018 recommendations, status of HCV screening: successes, challenges, and plans to address challenges  TAG (0.8.4)	<b>Dr. Amiran Gamkrelidze</b> , NCDC
12:15-1:30	Discussion by TAG/Q & A	
1:30-2:30	Lunch	

2:30-3:30	Provide HCV Care and Treatment	TAG moderators: Dr. Graham Foster, University of London, UK & Dr. Jorge Mera, Cherokee Nation, US <u>Discussants</u> : Tengiz Tsertvadze, IDACIRC, Eka Adamia, MOH, Lali Sharvadze, IDACIRC, Akaki Abutidze, IDACIRC, Uka Kiladze, National Family Medicine Center, Maia Butsashvili, HRU, Jaba
		Zarkua, Clinic Mrcheveli, Maka Gogia, GHRN
2:30-2:50	TAG 2018 recommendations, status of HCV care and treatment:     successes, challenges, and plans to address challenges including     simplified testing and cure strategies in decentralization of HCV services	Dr. Tengiz Tsertsvadze, IDACIRC
2:50-3:00	<ul> <li>Update on HCV screening, care and treatment in Georgia's Corrections System</li> </ul>	<b>TBD,</b> Ministry of Justice of Georgia, Special Penitentiary Service
3:00-3.30	Discussion by TAG/Q & A	
3.30-3:50	BREAK	
3:50-4:50	Promote Advocacy, Awareness, Education, and Partnerships for HCV-Associated Resource Mobilization	TAG moderators: Dr. Tatjana Reic, European Liver Patients Association, Croatia & Dr. Jeff Lazarus, EASL International Liver Foundation, Switzerland Discussants: Temur Radiani, Patient Association, Maia Butsashvili, HRU, Konstantine Rukhadze, GeCAB
3:50-4:05	<ul> <li>TAG 2018 recommendations, status of education/advocacy efforts: successes, challenges, and plans to address challenges</li> </ul>	Dr. Marina Topuridze, NCDC
4:05-4:50	<ul> <li>Round Table/Discussion by TAG/Q &amp; A</li> <li>Temur Radiani, Hepatitis C Cured Patient Association</li> <li>Maia Butsashvili, Health Research Union (HRU)</li> <li>Konstantine Rukhadze, Georgia Community Advisory Board (GeCAB)</li> <li>Maka Gogia, Georgia Harm Reduction Network</li> <li>Konstantine Labartkava, New Vector</li> </ul>	

4:50-5:50	Activities to Improve HCV Surveillance and Program Effectiveness	TAG moderators: Dr. Antons Mozalevskis, WHO-EURO, Denmark & Dr. Priti Patel, US CDC Discussants: Khatuna Zakhashvili, NCDC, Maia
		Butsashvili, HRU, Tinatin Kuchuloria, TEPHINET, Lia Gvinjilia, TEPHINET, Tsira Merabishvili, NCDC, Ketevan Galdavadze, NCDC, Maia Japaridze, FIND
4:50-5:15	<ul> <li>TAG 2018 recommendations, status of HCV surveillance: successes, challenges, and plans to address challenges</li> </ul>	Maia Tsereteli, NCDC
5:15-5:50	Discussion by TAG/Q & A	
5:50-6:00	Summary of Day 1 and Closing Remarks	Dr. Carolyn Wester, US CDC
6:30	Reception/Dinner at Republic hosted by FIND	

5 <sup>th</sup> Hepatitis C Technical Advisory Group (TAG) Meeting: Day 2 November 20, 2019		
TIME	PRESENTATIONS	SPEAKERS
9:00-9:15	Opening Remarks, Review Day 1	Dr. Carolyn Wester, US CDC (Chair) & Dr. Margaret Hellard, Burnet Institute, Australia (Co-Chair)
9:15-10:15	Prevent HCV Transmission i. Harm Reduction	TAG moderators: Dr. Margaret Hellard, Burnet Institute, Australia, Dr. Sharon Hutchinson, National Health Service, Scotland, UK Discussants: Irma Khonelidze, NCDC, Maka Gogia, GHRN, Konstantine Rukhadze, GeCAB
9:15-9:45	<ul> <li>TAG 2018 recommendations, update on prevention, screening and linkage to treatment of PWID</li> <li>Decentralization of HCV screening, care, and treatment in harm reduction settings</li> </ul>	Dr. Ketevan Stvilia, NCDC  Dr. Maia Butsashvili, Health Research Union
9:45-10:15	Discussion by TAG/Q & A	
10:15-10:35	BREAK	
10:35-11:15	Prevent HCV Transmission (continued) ii. Blood Safety	TAG moderators: Dr. Evan Bloch, Johns Hopkins University, US & Dr. Anders Widell, Lund University, Sweden Discussants: Khatuna Zakhashvili, NCDC, Vladimer Getia, NCDC, Maia Alkhazashvili, NCDC, Ketevan Shermadini, IDACIRC, Marina Baidauri, MOH, Radu Cojocaru, CDC
10:35-11:05	<ul> <li>TAG 2018 recommendations, status of blood safety program in blood banks: successes, challenges, and plans to address challenges</li> <li>Blood Bank screening quality assurance: Current practices and future directions</li> </ul>	Dr. Maia Alkhazashvili, NCDC  Dr. Nazibriola Chitadze, NCDC
11:05-11:15	Discussion by TAG/Q & A	

11:15-11:45	Prevent HCV Transmission (continued)  iii. Infection Control in Healthcare, Non-traditional Healthcare and Other	TAG moderators: Dr. Priti Patel, US CDC & Dr. Antons Mozalevskis, WHO-EURO, Denmark
	Community Settings	<u>Discussants</u> : David Tsereteli, NCDC, Marina Baidauri, MOH
11:15-11:25	TAG 2018 recommendations, status of infection prevention and control: successes, challenges, and plans to address challenges	<b>Dr. Marine Baidauri</b> , Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia (MOH)
11:25-11:45	Discussion by TAG/Q & A	
11:45-12:20	Improve HCV Laboratory Diagnostics	TAG moderators: Dr. Anders Widell, Lund University, Sweden & Dr. Evan Bloch, Johns Hopkins University, US Discussants: Nazibriola Chitadze, NCDC, Vladimer Getia, NCDC, Irma Khonelidze, NCDC, Maia Japaridze, FIND, Marika Karchava, IDACIRC, Lana Gatserelia, IDACIRC
11:45-12:00	<ul> <li>TAG 2018 recommendations, status of laboratory and diagnostics efforts: successes, challenges, and plans to address challenges including role of diagnostics in decentralization of HCV services</li> </ul>	Dr. Maia Alkhazashvili, NCDC
12:00-12:20	Discussion by TAG/Q & A	
12:20-1:20	Lessons Learned from Other Countries	TAG moderators: Dr. Carolyn Wester, US CDC & Dr. Carlos Del Rio, Emory University, USA
	Presentations	
12:20-1:00	<ul> <li>Australia</li> <li>Scotland, UK</li> <li>Cherokee Nation</li> </ul>	Dr. Margaret Hellard, Burnet Institute, Australia Dr. Sharon Hutchinson, National Health Service, Scotland, UK Dr. Jorge Mera, Cherokee Nation, USA
1:00-1:20	Round Table Discussion	
1:20-4:20	Lunch for All and Free Time TAG Members Lunch	
4:20-5:50	TAG Recommendations and 2019 Priorities	Dr. Carolyn Wester, US CDC & Dr. Margaret Hellard, Burnet Institute, Australia & TAG members
5:50-6:00	Closing Remarks	Dr. Carolyn Wester, US CDC